Results 211 to 220 of about 115,529 (261)

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Artificial intelligence-powered H&E-based quantification of spatial tumor-infiltrating lymphocyte distribution identifies prognostic immune niches in colorectal cancer. [PDF]

Cancer Immunol Immunother
Koh HH, Lee S, Oum C, Song S, Cho SI, Pereira S, Ahn CH, Kim JY, Kim M, Jung M.   +9 more
europepmc   +1 more source

High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes. [PDF]

Cancers (Basel)
Shiratori S, Kawakubo K, Hatanaka KC, Kobayashi T, Konishi T, Shinomiya Y, Oda S, Nozawa S, Yonemura H, Sugiura R, Harada K, Nakanishi Y, Noji T, Tanaka S, Hirano S, Kuwatani M, Hatanaka Y, Sakamoto N.   +17 more
europepmc   +1 more source

Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial. [PDF]

BMC Cancer
Özcan D, Nielsen PS, Alsner J, Nielsen MH, Maae E, Milo MLH, Overgaard J, Offersen BV, Tramm T.   +8 more
europepmc   +1 more source

Prognostic Significance of Selected Tumor Stroma Parameters in Patients with HER2-Positive Breast Cancer Treated with Adjuvant Trastuzumab. [PDF]

Cancers (Basel)
Ambicka A, Grela-Wojewoda A, Niemiec J, Mularz K, Harazin-Lechowska A, Ryś J, Adamczyk A.   +6 more
europepmc   +1 more source

PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy. [PDF]

J Transl Med
Ducoin K, Beauvais T, Goward J, Ahondo M, Lambot S, Mordelet A, Daminette A, Thabot M, Deng J, Tian S, Rulli S, Quereux G, Khammari A, Labarrière N.   +13 more
europepmc   +1 more source

Rewriting microenvironment immunity in glioblastoma. [PDF]

Mol Ther Oncol
Figg JW, Flores CT.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor-Infiltrating Lymphocytes

The Cancer Journal, 2015
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 has shown reproducible objective response rates of approximately 50% in patients with highly advanced, refractory metastatic melanoma.
Michal J, Besser, Ronnie, Shapira-Frommer, Jacob, Schachter   +2 more
openaire   +3 more sources